Campillo J A, Lanao J M, Dominguez-Gil A, Tabernero J M, Rubio F
Int J Clin Pharmacol Biopharm. 1979 Sep;17(9):416-20.
The pharmacokinetics of Cefamandole was studied in 17 patients with terminal renal impairment, 10 of which were undergoing sessions of hemodialysis while 7 were in the period between dialysis sessions. An open two-compartment kinetic model was used to describe the bi-phasic decrease of the plasma concentrations of Cefamandole thus establishing the amounts of the antibiotic in the peripheral and central compartments together with the amount eliminated. All patients received an i.v. bolus injections of 15 mg/kg body weight. During the hemodialysis sessions, the pharmacokinetic parameters of Cefamandole were the following: alpha = 5.006 hr-1 beta = 0.182 hr-1 K12 = 2.598 hr-1 K21 = 2.147 hr-1 K13 = 0.441 hr-1 Vc = 5.700 l Vp = 6.190 l Vdss = 11.94 l It may be seen that there is a decrease in the overall elimination constant compared with that obtained during the periods between the dialysis sessions. A dosage regimen of multiple doses is established as a function of the pharmacokinetic parameters of the antibiotic for patients with terminal renal impairment undergoing periodic sessions of hemodialysis.
在17例终末期肾功能损害患者中研究了头孢孟多的药代动力学，其中10例正在进行血液透析治疗，7例处于透析间期。采用开放二室动力学模型描述头孢孟多血浆浓度的双相下降，从而确定外周室和中央室中抗生素的量以及消除量。所有患者均接受了15mg/kg体重的静脉推注。在血液透析治疗期间，头孢孟多的药代动力学参数如下：α=5.006小时-1，β=0.182小时-1，K12=2.598小时-1，K21=2.147小时-1，K13=0.441小时-1，Vc=5.700升，Vp=6.190升，Vdss=11.94升。可以看出，与透析间期相比，总体消除常数有所下降。根据正在接受定期血液透析治疗的终末期肾功能损害患者的抗生素药代动力学参数，制定了多剂量给药方案。
